Health2Sync 智抗糖

Health2Sync 智抗糖 is a Taiwan-based startup that aims to facilitate the improvement of chronic disease patients' health condition through personalized digital therapeutics. Founded in June 2013, the company offers a comprehensive health management platform, connecting patients with family, friends, and care providers. Its flagship product, the Health2Sync mobile app, enables diabetes patients to easily track their blood sugar and related factors. The company has garnered recognition, with the Health2Sync app being selected as one of the "10 Best Diabetes Apps" by Healthline for three consecutive years since 2017 and boasting over 1.2 million users worldwide presently. Additionally, Health2Sync is venturing into digital therapeutic development to enhance the self-management of blood glucose. The latest milestone for the company was a Series B investment on 15 August 2022. With its focus on leveraging technology to innovate and enhance convenience in the health and medical field, Health2Sync presents an intriguing opportunity for venture capital investors.